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ABSTRACT  24 
Many neural sex differences are differences in the number of neurons of a particular phenotype. 25 
For example, male rodents have more calbindin-expressing neurons in the medial preoptic area 26 
(mPOA) and bed nucleus of the stria terminalis (BNST), and females have more neurons 27 
expressing estrogen receptor alpha (ERα) and kisspeptin in the ventromedial nucleus of the 28 
hypothalamus (VMH) and the anteroventral periventricular nucleus (AVPV), respectively. These 29 
sex differences depend on neonatal exposure to testosterone, but the underlying molecular 30 
mechanisms are unknown. DNA methylation is important for cell phenotype differentiation 31 
throughout the developing organism. We hypothesized that testosterone causes sex differences in 32 
neurochemical phenotype via changes in DNA methylation, and tested this by inhibiting DNA 33 
methylation neonatally in male and female mice, and in females given a masculinizing dose of 34 
testosterone. Neonatal testosterone treatment masculinized calbindin, ERα and kisspeptin cell 35 
number of females at weaning. Inhibiting DNA methylation with zebularine increased calbindin 36 
cell number only in control females, thus eliminating sex differences in calbindin in the mPOA 37 
and BNST. Zebularine also reduced the sex difference in ERα cell number in the VMH, in this 38 
case by increasing ERα neuron number in males and testosterone-treated females. In contrast, the 39 
neonatal inhibition of DNA methylation had no effect on kisspeptin cell number. We conclude 40 
that testosterone normally increases the number of calbindin cells and reduces ERα cells in males 41 
through orchestrated changes in DNA methylation, contributing to, or causing, the sex 42 




Many sex differences in the mammalian brain are established by a transient, perinatal 46 
exposure to gonadal testosterone in males  (1–3). In some cases, testosterone regulates neuronal 47 
cell death to cause sex differences in neuron number (4,5); however, other sex differences persist 48 
even if developmental cell death is eliminated. For example, males have more neurons 49 
expressing calbindin in the medial preoptic area of the hypothalamus [mPOA, (6,7)] and 50 
vasopressin in the bed nucleus of the stria terminalis [BNST, (8,9)], whereas females have more 51 
neurons expressing tyrosine hydroxylase and kisspeptin in the anteroventral periventricular 52 
nucleus and neighboring rostral periventricular nucleus [AVPV/PeN, (10–12)]. These sex 53 
differences all persist in mice lacking the pro-death gene Bax (13–16), despite the near complete 54 
elimination of developmental neuronal cell death in Bax knockout mice (17,18).  55 
 Epigenetic modifications to chromatin control gene expression and are required for the 56 
differentiation of cell phenotype throughout development. Two of the best studied epigenetic 57 
modifications are the acetylation of histone tails and the methylation of cytosine residues of 58 
DNA, and both have been implicated in the sexual differentiation of brain anatomy and behavior 59 
(19–21). DNA cytosine methylation is controlled by a family of DNA methyltransferases 60 
(DNMTs) that place methyl marks, and ten-eleven translocases (TET enzymes) that remove 61 
those marks (22–24). DNA methylation is normally associated with gene repression, although 62 
there are exceptions (25). The expression of DNMT enzymes peaks during the first postnatal 63 
week in the mouse brain (26,27), which coincides with the critical period for testosterone-64 
dependent sexual differentiation. Moreover, there are sex differences in DNMT and TET activity 65 
and/or expression in the neonatal brain (21,26). We therefore hypothesized that sex differences 66 
 4 
in neurochemical phenotype (i.e., the number of cells expressing specific markers) may depend 67 
on differential DNA methylation in males and females. 68 
In a first test of this idea (28), we previously administered a DNMT inhibitor to newborn 69 
male and female mice, and examined effects on the male-biased sex difference in calbindin cell 70 
number in the mPOA, and the female-biased sex difference in the number of estrogen receptor 71 
(ER) α cells in the ventrolateral portion of the ventromedial hypothalamus [VMHvl, (29–31)]. 72 
The neonatal inhibition of DNA methylation increased the number of cells expressing both cell 73 
types at weaning (28), consistent with the canonical association of DNA methylation with the 74 
suppression of gene transcription, and also reduced or eliminated the sex differences in calbindin 75 
and ERα cell number (28).  76 
 Calbindin cell number in the mPOA is masculinized in female rats and mice treated with 77 
testosterone or estradiol at birth, and the sex difference is present prior to puberty (15,32,33). 78 
The sex difference in ERα in the VMHvl is also evident prior to puberty in rats and mice 79 
(28,31,34), although its dependence on neonatal testosterone has not yet been demonstrated. 80 
Here, we hypothesized that testosterone causes these sex differences in cell phenotype (a 81 
decrease in ERα and an increase in calbindin) by orchestrating changes in DNA methylation 82 
around the time of birth. If so, then effects of endogenous or exogenous testosterone may be 83 
prevented by inhibiting DNA methylation.  84 
To test this, we administered a masculinizing dose of testosterone to female mice 85 
concomitant with intracerebroventricular (icv) injections of a DNMT inhibitor or vehicle during 86 
the critical period of sexual differentiation, and examined effects on calbindin in the mPOA and 87 
ERα in the VMHvl at weaning. We also extended our observations to two additional sex 88 
differences in neurochemical phenotype: calbindin cell number in the BNST [which is normally 89 
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greater in males, (15)] and kisspeptin cell number in the AVPV/PeN [greater in females; 90 
(10,16)]. We find that neonatal inhibition of cytosine methylation eliminates or reduces sex 91 
differences in calbindin and ERα. Interestingly, it does so by increasing cell counts specifically 92 
in those groups in which the cell type of interest is normally repressed (i.e., calbindin cells in 93 
females and ERα cells in males and testosterone-treated females).  94 
 95 
MATERIALS AND METHODS 96 
 97 
Animals  98 
Wildtype C57BL6/J mice were purchased from Jackson Laboratory (Bar Harbor, ME). Breeding 99 
pairs were housed in a 12:12 light:dark cycle at 22 C with food (LabDiet 5015, St. Louis, MO, 100 
USA) and water available ad libitum and were checked daily for births. All procedures were 101 
performed in accordance with the National Institutes of Health animal welfare guidelines and 102 
were approved by the Georgia State University Institutional Animal Care and Use Committee.  103 
 104 
Zebularine injections 105 
DNA methylation was inhibited using zebularine (Calbiochem, San Diego, CA), a cytidine 106 
analog and global DNMT inhibitor that has been used in many rodent studies due to its low 107 
toxicity (35,36). Cryoanesthetized pups received icv injections of 300 ng zebularine into each 108 
hemisphere (in 500 nL 10% dimethyl sulfoxide, 90% physiological saline), or the vehicle alone, 109 
on postnatal day (P) 0 (the day of birth) and P1. This dose was chosen based on our own 110 
previous work and that of others (21,28). A 30 gauge needle attached to a 5µl Hamilton syringe 111 
was lowered 2 mm below the skull, at approximately 1 mm rostral to lambda and 1 mm lateral to 112 
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the sagittal suture. Zebularine or vehicle was injected at a rate of 33 nL/sec using a Micro4 113 
microsyringe pump (World Precision Instruments, Sarasota, FL).  114 
 115 
Testosterone injections and brain collection 116 
Concomitant with zebularine or vehicle injections, female newborns received 117 
subcutaneous injections of either testosterone propionate (Sigma, St Louis, MO; 100 g in 25 L 118 
of peanut oil as in (37)] or the oil vehicle on P0 and P1; all males received the vehicle only. 119 
Animals in each group were derived from at least six different litters, and were sacrificed at 120 
weaning on P25, as previously (28), to avoid effects of pubertal hormones. Brains were fixed by 121 
immersion in 5% acrolein for 24 hours, then transferred to 30% sucrose in 0.1 M phosphate 122 
buffer before sectioning into four coronal series of 30 microns. Sections were stored in 123 
cryoprotectant (30% sucrose, 30% ethylene glycol in 0.1 M phosphate buffer, 1% 124 
polyvinylpyrrolidone) until staining. 125 
 126 
Immunohistochemistry for calbindin, ER, and kisspeptin  127 
 One  series of sections was stained for calbindin [mouse anti-calbindin, 1:20,000 anti-128 
calbindin-D28k; Sigma; (38)], one for ER [rabbit anti-ERα, 1:20,000; EMD Millipore, 129 
Billerica, MA; (39)], and one for kisspeptin [rabbit anti-kisspeptin, 1:2,000; EMD 130 
Millipore;(40)]. Protocols are described in detail elsewhere (28). Briefly, on the first day tissue 131 
was incubated in 0.1 M glycine for 30 minutes, extensively rinsed in 1X tris 132 
(hydroxymethyl)aminomethane-buffered saline (TBS), incubated in a blocking solution (1X 133 
TBS, 10% normal goat serum, 1% hydrogen peroxide, and 0.4% Triton-X), followed by an 134 
overnight incubation in primary antibody. On the next day, secondary antibodies used were 135 
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biotinylated goat anti-mouse [1:500 for calbindin, Vector Laboratories, Burlingame, CA (41)], or 136 
biotinylated goat anti-rabbit [1:250 for ER and 1:500 for kisspeptin, Vector Laboratories (42)]. 137 
Staining was visualized using an avidin-biotin complex followed by incubation in 138 
diaminobenzidine-nickel (Vector Laboratories).  139 
 140 
Cell-type quantification 141 
The number of cells positive for calbindin in the mPOA and BNST, ER in the VMHvl, and 142 
kisspeptin in the AVPV/PeN was counted with the aid of Stereo Investigator software (MBF 143 
Bioscience, Williston, VT). The counting strategy for each cell group was based on the size and 144 
cell number of each region, and all analyses were performed by an experimenter blind to group 145 
membership. For calbindin in the mPOA, an ellipsoidal contour (300 μm major axis, 180 μm 146 
minor axis) was superimposed around the region of interest [Figures 31-34 in the Paxinos & 147 
Franklin mouse brain atlas (43)]. Labeled cells within the contours were counted in the left and 148 
right hemispheres of at least two brain sections and the two highest counts were summed, as 149 
previously (15). Calbindin-positive cells in the encapsulated portion of the BNST [Figure 31 in 150 
(43)] were quantified as previously (44) using the particle counter function of ImageJ (Version 151 
1.47; National Institutes of Health, Bethesda, MD). For the VMHvl, a contour was manually 152 
drawn on each hemisphere based on the characteristic shape and location of the nucleus [Figures 153 
42-47 in (43)], labeled cells within the contours were counted, and sections with the four highest 154 
counts of ER cells were summed for each animal. For kisspeptin, the AVPV/PeN region was 155 
identified using the anterior commissure and third ventricle as landmarks [Figures 29-33 in (43)], 156 
and all labeled cells in all sections were counted. Animals for which the sections of interest were 157 
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damaged, folded, or missing were omitted from the analysis (final N in each group is indicated at 158 
the base of each bar in the figures).  159 
 160 
Efficacy of zebularine treatment 161 
To confirm the efficacy of our treatments, we examined DNMT activity in a separate cohort of 162 
newborns (all males) that received zebularine or vehicle as above, and were sacrificed six or 24 163 
hours after the last injection (P1-P2). The mediobasal hypothalamus was manually dissected and 164 
kept at -80 C until processing. Nuclear protein was purified using the EpiQuik Nuclear 165 
Extraction Kit 1 (Epigentek, Farmingdale, NY; OP-0002) and quantified by BCA Protein Assay 166 
(Thermo Scientific; 23252). Total DNMT activity was evaluated using the EpiQuik DNMT 167 
Activity Assay Ultra Kit (Epigentek; P-3010), according to the manufacturer instructions. The 168 
DNMT activity was calculated using the formula: DNMT Activity (RFU/h/mg protein) = 169 
[(Sample RFU – Blank RFU) / (Protein Amount (μg)* x 2 hours)] x 1000 where RFU are the 170 
relative fluorescent units measured.  171 
 172 
Statistical analyses 173 
Data were checked for normality and homogeneity of variance using IBM SPSS Statistics. 174 
DNMT activity after zebularine injections was analyzed using two-tailed independent t-tests. A 175 
priori predictions about sex differences and the effect of neonatal testosterone were evaluated by 176 
two-tailed independent t-tests. The effects of group (males, females, masculinized females) and 177 
treatment (zebularine, vehicle) on the number of cells expressing specific phenotypes were 178 
analyzed with two-way ANOVA using Graph Pad Prism. ANOVA was followed by Fisher’s 179 
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least significance difference (LSD) post hoc test when appropriate, and P < 0.05 was considered 180 




Zebularine transiently decreases global DNMT activity 185 
Zebularine reduces DNA methylation within one hour in hippocampal slice cultures (45), 186 
and icv injections to adult rats reduce DNA methylation in the brain within four hours (46). 187 
However, few studies have performed a time course for zebularine effects and, to our 188 
knowledge, no studies have examined this in the neonatal brain. To confirm the efficacy of our 189 
injections, DNMT activity was examined in the hypothalamus six or 24 hours after injections of 190 
zebularine to newborns on P0 and P1. Compared to vehicle controls, zebularine-treated animals 191 
experienced a 54% reduction in global DNMT activity six hours after treatment (t6 = 3.32; P < 192 
0.02), and activity had returned to control levels by 24 hours after the last injection (t6 = 1.84; P 193 
> 0.80, Figure 1). Thus, zebularine transiently decreased global DNMT activity.  194 
 195 
Neonatal inhibition of DNA methylation increases calbindin cell number only in females  196 
As expected, control males had more calbindin-positive cells in the mPOA than control 197 
females at weaning (t20 = 3.60; P < 0.002; Figure 2). Neonatal testosterone treatment of females 198 
increased calbindin cell number (t16 = 5.33; P < 0.0001) and eliminated this sex difference. If the 199 
sex difference in calbindin cell number was due to differential DNA methylation among groups, 200 
then it might be inhibited by neonatal treatment with zebularine. Indeed, we found a main effect 201 
of group (F2, 62 = 10.91, P < 0.0001) as well as a group-by-treatment interaction (F2, 62 = 5.05, P 202 
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< 0.01) on calbindin cell number in the two-way ANOVA (Figure 2B). Calbindin cell number 203 
was significantly higher in control males and testosterone-treated females than in control females 204 
(P < 0.0001 for both comparisons). Neonatal zebularine treatment increased calbindin cell 205 
number at weaning only in control females (P < 0.02) and was as effective as testosterone in this 206 
regard (female + testosterone vs female + zebularine, P = 0.66). As a result, group differences 207 
were abolished in zebularine-treated mice.  208 
The same general pattern was seen for calbindin cells in the BNST. We confirmed that 209 
the sex difference in calbindin cell number previously seen in the BNST of adults (15) is present 210 
prior to puberty (control male versus control female, t21 = 2.23; P < 0.04; Figure 3). There was a 211 
trend for a higher number of calbindin-positive cells in the female + testosterone group compared 212 
to control females, but this did not reach significance (P < 0.1). By two-way ANOVA, we found 213 
a significant effect of zebularine treatment on calbindin cell number (F1, 61 = 4.02, P < 0.05; 214 
Figure 3B): zebularine increased the number of calbindin-positive neurons overall, and within 215 
groups this was significant only for females (P < 0.05).  216 
These findings suggest that DNA methylation normally decreases calbindin cell number 217 
in the mPOA and BNST of females.  218 
 219 
Neonatal inhibition of DNA methylation partially prevents the masculinizing effect of 220 
testosterone on ERα cell number  221 
In contrast to the male-biased sex differences in calbindin cell number, females have 222 
more ERα neurons in the VMHvl than do males. We confirmed this sex difference and found 223 
that neonatal testosterone decreased ERα cell number at weaning in females (control female vs 224 
testosterone-treated female, t13 = 9.89; P < 0.0001) to a level indistinguishable from that in males 225 
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(Figure 4). In the ANOVA, we found significant main effects of group (F2, 53 = 80.1, P < 0.0001) 226 
and zebularine treatment (F1, 53 = 4.75, P = 0.034), as well as a group-by-treatment interaction 227 
(F2, 53 = 5.03, P = 0.01; Figure 4). Inhibition of DNA methylation increased ERα cell number 228 
overall, in a pattern that was the mirror image of that seen for effects on calbindin cell number: 229 
significant for males and testosterone treated-females (P < 0.03 in both cases), with no effect in 230 
females. As a result, the magnitude of the sex difference was reduced, although not eliminated, 231 
in zebularine-treated animals.   232 
 233 
DNMT inhibition does not alter kisspeptin cell number 234 
As expected, we found a marked sex difference in kisspeptin cell number in the 235 
AVPV/PeN of vehicle-treated mice, with many more kisspeptin-positive cells in females (t16 = 236 
12.89; P < 0.0001). Neonatal testosterone treatment decreased kisspeptin cell number in females 237 
(t15 = 11.90; P < 0.0001) to a level nearly identical to that in males. We did not find evidence of a 238 
role for DNA methylation in the development of this sex difference: two-way ANOVA found a 239 
significant main effect of group on kisspeptin cell number (F2, 47 = 258.6, p < 0.0001; Figure 5), 240 
with no effect of zebularine and no group-by-treatment interaction. There was, however, a trend 241 




Neonatal testosterone (or its estrogenic metabolites) can alter DNA methylation patterns 246 
in the brain (21,47,48). To test the hypothesis that hormone exposure is “encoded” by changes in 247 
DNA methylation, which underlie sex differences in the number of cells expressing phenotypic 248 
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markers, we inhibited DNMT activity during the neonatal critical period for sexual 249 
differentiation in mice. Our findings support the conclusion that DNA methylation contributes to 250 
sex differences in calbindin cell number in the mPOA and BNST, and ER𝛼 cell number in the 251 
VMHvl, but not to kisspeptin cell number in the AVPV/PeN.  252 
Males have more calbindin-positive neurons than do females in the mPOA and BNST, 253 
and treating females with testosterone at birth masculinized both cell groups. Similarly, the 254 
neonatal inhibition of DNA methylation increased the number of calbindin cells in both regions 255 
only in females, and eliminated the normal sex differences. This suggests that females have 256 
neurons in the mPOA and BNST with the potential to express calbindin, but that are prevented 257 
from doing so by DNA methylation.  258 
The female-biased sex difference in ERα cell number in the VMHvl at weaning was also 259 
completely eliminated by treating newborn females with testosterone and, in this case, neonatal 260 
DNMT inhibition increased the number of ERα cells in males and testosterone-treated females, 261 
with no effect in control females. Thus, DNA methylation is at least partly responsible for 262 
suppressing ERα cell number in males and masculinized females. Zebularine did not fully 263 
increase ERα cell number in males and testosterone-treated females to female-like levels, 264 
however. This may be related to the fact that the inhibition of DNMT activity we achieved was 265 
partial (a 54% reduction at 6 h), and a more profound inhibition may be required for female-like 266 
development of the ERα phenotype. Alternatively, mechanisms other than cytosine methylation 267 
may be involved; this might, for example, include histone modifications, or non-cytosine DNA 268 
methylation. Recently, methylation of other bases (especially, adenine) has been demonstrated in 269 
neurons (27) and zebularine, a cytidine analog, would not be expected to inhibit adenine 270 
methylation.   271 
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An increase in cell number after neonatal zebularine treatment could, in principle, be due 272 
to a change in cell phenotype (i.e., cells now express the marker of interest) or a decrease in 273 
developmental cell death (i.e., more cells survive). The evidence in favor of a change in cell 274 
phenotype is strong for the calbindin cell groups examined here. First, sex differences in 275 
calbindin cell number in the mPOA and BNST persist even when developmental cell death is 276 
prevented (15).  In addition, we previously found no change in developmental cell death and no 277 
change in total cell number in the mPOA at weaning after neonatal zebularine treatment (28). 278 
Thus, early-life inhibition of DNA methylation changes the number of cells that express 279 
calbindin, without changing total cell number. We also found no effect of neonatal zebularine 280 
treatment on cell death in the VMHvl (28). However, total cell number in the VMHvl was not 281 
examined, and the ER sex difference has not been examined in cell death mutant mice. Thus, 282 
the conclusion that zebularine changes cell phenotype independent of a change in cell number for 283 
ER is more tentative, and awaits confirmation. 284 
Total DNMT activity was markedly decreased at 6 hours, but not at 24 hours, after 285 
neonatal zebularine treatment. Despite the transient suppression, effects on calbindin and ERα 286 
cell number were long-lasting (i.e., to at least 3.5 weeks of age). This suggests that early life 287 
disruptions in DNA methylation may have programming effects on neuronal phenotype. Patterns 288 
of DNA methylation and its counterpart, hydroxymethylation, are dynamic during postnatal 289 
development (26,27,48,49). Previous studies have shown that pharmacological perturbations to 290 
epigenetic mechanisms do not globally affect the genome, but may particularly target genes 291 
undergoing active regulation (50). The present results suggest that this includes genes subject to 292 
hormone-dependent sexual differentiation during perinatal life. In the mPOA of rats, sexual 293 
differentiation of male copulatory behavior and dendritic spine density remained sensitive to 294 
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inhibition of DNA methylation as late as postnatal day 10 (21). It will be interesting to determine 295 
whether transient epigenomic disruptions later in life would impact neurochemical phenotype or, 296 
alternatively, whether there is a perinatal critical window for establishing the number of cells 297 
with the potential to express specific markers.  298 
Gonadal steroids may alter DNA methylation by controlling the expression or activity of 299 
methylating and demethylating enzymes. For example, females have higher DNMT activity 300 
and/or gene expression in the neonatal mPOA (21,26), as well as lower expression of the TET 301 
enzymes that are responsible for de-methylation (26). Thus, the balance is shifted to greater 302 
methylation in females. Because calbindin cell number in the mPOA is reduced in females 303 
compared to males, the sex differences in enzyme expression/activity are consistent with the 304 
canonical effect of DNA methylation to inhibit gene expression.  305 
Other sex differences are not as easy to reconcile with the usual association of DNA 306 
methylation with transcription inhibition. For example, females have greater expression than 307 
males of some genes in the mPOA (30,31), and TET enzyme expression is higher in males than 308 
in females in the neonatal VMH (26), yet males have a reduced number of ERα cells. It is likely 309 
that some of the effects of testosterone, or neonatal DNMT inhibition, are due to methylation 310 
changes directly on the genes in question, whereas others are indirect. For example, a reduction 311 
in DNA methylation may favor the expression of an upstream gene(s) that represses the ERα 312 
gene (Esr1) in males. Alternatively, a growing number of examples contradict the canonical 313 
association of DNA methylation with transcriptional repression, supporting a cell type or 314 
genomic context-specific role of DNA methylation [(51–53)], and that could be true of the genes 315 
encoding the cell-type markers examined here. Methods such as bisulfite sequencing can be used 316 
in future studies to determine whether sex differences in cell phenotype correlate with changes in 317 
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methyl or hydroxymethyl marks in promoter regions of the genes of interest, but it will be much 318 
more challenging to demonstrate that any one epigenetic mark (or groups of marks) actually 319 
cause observed differences in expression or cell phenotype. 320 
We found an enormous, 40-fold sex difference in kisspeptin cell number (female > male) 321 
in the AVPV/PeN of weanlings. This is consistent with a previous observation that the sex 322 
difference in this region emerges prior to puberty in mice (10). In rats, the sex difference in 323 
kisspeptin cell number in the AVPV/PeN results from early life exposure to testosterone and its 324 
estrogenic metabolites (11,54), and our findings confirm a similar mechanism for mice. 325 
However, the neonatal inhibition of DNA methylation had no effect on kisspeptin cell number in 326 
males or females, and also did not prevent the masculinizing effect of testosterone in females. 327 
Semaan et al. (55) previously investigated epigenetic mechanisms in the sexual differentiation of 328 
kisspeptin cell number in the AVPV/PeN. Although they found a difference in DNA methylation 329 
of the Kiss1 gene promoter between male and female mice, it was in the opposite direction to 330 
that expected (lower methylation in males). Moreover, an impairment of CpG-binding protein-2, 331 
which binds to methylated DNA to form a repressive complex, did not affect the sex difference 332 
in kisspeptin cell number, and an inhibition of histone acetylation in newborn mice also did not 333 
reduce the sex difference in kisspeptin in the AVPV/PeN (55). Taken together with the current 334 
study, there is not compelling evidence linking DNA methylation or histone acetylation to the 335 
sex difference in kisspeptin cell number in the AVPV/PeN, although additional studies are 336 
clearly needed before either mechanism can be ruled out. 337 
Differences in neurochemical phenotype may be the most common type of sex difference 338 
in the nervous system, yet relatively little is known about underlying molecular mechanisms. Our 339 
findings suggest that the regulation of neurochemical phenotype by DNA methylation is cell-340 
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type specific, and that DNA methylation underlies both feminization [as shown by calbindin cell 341 
number in the present study and (21)], and masculinization [ERα cell number in the present 342 
study and (28)] of neuronal cell phenotype. The scenario is likely to be even more nuanced than 343 
the relatively simple examples examined here. In regions such as the VMHvl, for example, ER𝛼-344 
expressing neurons are not a homogenous cell group, but are comprised of multiple subtypes, 345 
with various projections and functions (56–60). Males and females start out with an equally high 346 
number of ER𝛼 neurons in the VMHvl at birth (28), and we are currently examining whether the 347 
sex difference that emerges by weaning is the consequence of testosterone-dependent DNA 348 
methylation in some, but not all, Esr1 lineage subtypes in males. Given the crucial role of 349 
neurochemistry in neuron function, the “decision” of a cell to express or not express a given 350 
receptor (e.g., ER𝛼), or calcium-binding protein (e.g. calbindin) will have clear functional 351 
consequences for the entire neural circuit, as well as the functions and behaviors it controls. 352 
  353 
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FIGURE LEGENDS 354 
 355 
Figure 1: DNMT activity is transiently reduced after zebularine treatment. Compared to 356 
vehicle-treated controls, total DNMT activity in the mediobasal hypothalamus was reduced by 357 
54% six hours after icv zebularine injections in neonatal mice. There was no difference in 358 
DNMT activity relative to vehicle controls at 24 hours after treatment. * P < 0.05. Data are mean 359 
± SEM. The number of animals per group is indicated at the base of each bar.  360 
 361 
Figure 2: Neonatal zebularine increased calbindin cell number in the medial preoptic area 362 
(mPOA) only in females. A) Photomicrographs showing calbindin-positive (CALB+) cells in 363 
the mPOA at weaning in males, females, and testosterone- (T-) treated females that received icv 364 
vehicle or zebularine at birth. 3V: third ventricle. B) Quantification of CALB+ cell number 365 
shows that males and testosterone-treated females had more CALB+ cells on P25 than did 366 
control females (gray horizontal lines with asterisks). Neonatal treatment with zebularine 367 
increased CALB+ cell number only in females (black horizontal line) and eliminated group 368 
differences. The number of animals per group is indicated at the base of each bar. * P < 0.05; ** 369 
P < 0.01; **** P < 0.0001. Data are mean ± SEM.  370 
 371 
 372 
Figure 3: Neonatal zebularine increased calbindin cell number in the bed nucleus of the 373 
stria terminalis (BNST) only in females. A) Photomicrographs showing calbindin-positive 374 
(CALB+) cells in the encapsulated portion of the BNST at weaning in males, females, and 375 
testosterone- (T-) treated females that received icv vehicle or zebularine at birth. B). 376 
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Quantification of CALB+ cell number at weaning. Control males had more CALB+ cells than 377 
control females in an a priori t-test (P < 0.05), although the main effect of group in the ANOVA 378 
did not reach significance. Neonatal zebularine treatment increased CALB+ cell number overall 379 
at P25, and this was significant only for females. The number of animals per group is indicated at 380 
the base of each bar. * P < 0.05. Data are mean ± SEM.  381 
 382 
Figure 4: Neonatal zebularine increased estrogen receptor α (ERα) cell number in the 383 
ventrolateral portion of the ventromedial hypothalamus (VMHvl) of males and 384 
testosterone-treated females. A) Photomicrographs of ERα cells in the VMHvl at weaning in 385 
males, females, and testosterone-treated females that received icv vehicle or zebularine at birth. 386 
B) Quantification of ERα cell number at weaning demonstrates that vehicle-treated females had 387 
more ERα cells than males or testosterone-treated females (Female + T). There was a significant 388 
interaction between group and zebularine treatment, such that neonatal zebularine increased ERα 389 
cell number in males and testosterone-treated females, but not in females. Gray horizontal lines 390 
with asterisks indicate significant effects of sex and black horizontal lines indicate significant 391 
effects of zebularine. The number of animals per group is indicated at the base of each bar. * P < 392 
0.05; **** P < 0.0001. Data are mean ± SEM.  393 
 394 
Figure 5: Inhibition of DNMT activity at birth did not affect the highly sexually dimorphic 395 
group of kisspeptin cells in the anteroventral periventricular nucleus / rostral 396 
periventricular region (AVPV/PeN).  A) Photomicrographs of kisspeptin+ cells in the 397 
AVPV/PeN at weaning in males, females, and testosterone-treated females that received icv 398 
vehicle or zebularine at birth. 3V: third ventricle.  B) Quantification reveals that females had 40-399 
 19 
fold more kisspeptin-positive cells than did males or testosterone-treated females at weaning. 400 
Neonatal zebularine treatment did not significantly affect kisspeptin cell number.  Gray 401 
horizontal bars indicate significant effects of sex . The number of animals per group is indicated 402 
at the base of each bar.  **** P < 0.0001. Data are mean ± SEM.   403 
 20 
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